Replimune Group (REPL)
(Real Time Quote from BATS)
$6.57 USD
+0.16 (2.50%)
Updated May 13, 2024 03:28 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 41 - 60 ( 191 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Continues to Deliver Promising Data in Melanoma and CSCC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Several Data Updates Expected in CY2022; FY2022 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q4; Positive Clinical Data Updates; Going Deep with RP2/3
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
FY2022: Data-Rich 2022 Ahead. Early-Stage Program Execution is Critical.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Program Highlights and Future Directions from R&D Event
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
F3Q22 Results Announced; Numerous CY2022 Data Catalysts; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology-Looking into 1Q22, Cash Balance, & Price Target Changes
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
3Q: March Investor Event is of Prime Importance
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T